share_log

Short Interest in Q BioMed Inc. (OTCMKTS:QBIO) Drops By 99.5%

kopsource ·  Jul 29, 2022 16:11

Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totalling 100 shares, a drop of 99.5% from the June 30th total of 19,200 shares. Based on an average daily trading volume, of 844,800 shares, the short-interest ratio is currently 0.0 days.

Q BioMed Price Performance

Shares of QBIO traded down $0.01 during mid-day trading on Friday, hitting $0.17. 453,350 shares of the company's stock were exchanged, compared to its average volume of 234,883. The company has a market cap of $7.05 million, a PE ratio of -0.55 and a beta of 1.74. Q BioMed has a 52 week low of $0.04 and a 52 week high of $0.90. The company has a 50-day simple moving average of $0.08 and a 200 day simple moving average of $0.22.

Get Q BioMed alerts:

About Q BioMed

(Get Rating)

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.

See Also

  • Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
  • The One Question You Have to Ask Before Investing in INTC Stock
  • Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
  • Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
  • Why Apple Shares May Have Room to Move Higher After Earnings
  • Windfall Profits Have Exxon Mobil On Track For New Highs

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment